Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing

Friday, November 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab announced positive first-in-human data for ZL-1503, a bispecific antibody targeting IL-13 and IL-31Rα. The results from the Phase 1/1b trial showed rapid and sustained inhibition of key biomarkers for atopic dermatitis. The findings suggest a longer serum half-life, potentially allowing for less frequent dosing.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive first-in-human results reported.
  • Demonstrated rapid inhibition of atopic dermatitis biomarkers.
  • Extended serum half-life supports less frequent dosing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+63%
120-day peak, hindsight
Typical move
3.9%
average across 15 past catalysts
Cash runway
~29 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced positive preliminary, first-in-human results from the single-ascending-dose portion of its global Phase 1/1b trial of ZL-1503, an internally discovered, long-acting IL-13/IL-31 receptor alpha (Rα) bispecific antibody. Findings from the study will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scien

Frequently Asked Questions

What is ZL-1503?

ZL-1503 is an internally discovered, long-acting IL-13/IL-31Rα bispecific antibody.

What trial results were reported?

Positive preliminary first-in-human results from the single-ascending-dose portion of a Phase 1/1b trial.

What biomarkers did ZL-1503 inhibit?

It demonstrated rapid and sustained inhibition of key atopic dermatitis biomarkers.

Where will findings be presented?

Findings will be presented at the ACAAI 2026 Annual Scientific Meeting.

ShareAdd on Google
Tags: ZLAB Zai Lab ZL-1503 atopic dermatitis bispecific antibody Phase 1 trial
Last updated: Nov 13, 2026

Biotech snapshot

Cash runway
$560M liquidity · $19M/mo burn
~29 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+63%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →